CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Clinical Studies
Original article

LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia

Phase 3LB-102
Related Companies

Read the original article

Published by GlobeNewswire Clinical Studies on July 22, 2026 12:00 PM

Read Original